PRESS RELEASE
Published July 27, 2023
According to IMARC Group’s latest report, titled “Chronic Obstructive Pulmonary Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033”, The 7 major chronic obstructive pulmonary disease markets reached a value of US$ 13,061.7 Million in 2022. Looking forward, IMARC Group expects the 7MM to reach US$ 18,256.1 Million by 2033, exhibiting a growth rate (CAGR) of 3.08% during 2023-2033.This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the market in any form.
Industry Definition and Application:
Chronic obstructive pulmonary disease (COPD) stands for a long-term respiratory condition marked by unceasing airflow restriction, mainly caused by airway inflammation and lung tissue damage. Symptoms like breathlessness, wheezing, chest discomfort, chronic coughing, and overproduction of mucus often lead to difficulties in breathing, making everyday activities strenuous and impairing the quality of life for COPD patients. It may lead to weight loss, depression, and other systemic complications. The diagnostic process for COPD usually comprises a review of medical history, physical check-ups, lung function tests, and imaging examinations. The patient's history could cover inquiries about symptomatology, smoking habits, exposure to environmental pollutants, and any familial incidence of lung disorders. Imaging methods, such as chest X-rays or CT scans, are employed to pinpoint structural irregularities in the lungs, while blood tests might be used to rule out other possible causes of the symptoms.
Request for a Free Sample Copy of this Report:
www.imarcgroup.com/chronic-obstructive-pulmonary-disease-market/requestsample
What are the growth prospects and trends in the industry?
The chronic obstructive pulmonary disease market is growing due to the rise in long-term exposure to lung irritants, including tobacco smoke and air pollutants, which cause inflammation and narrowing of the airways. The increased presence of risk factors like exposure to chemical fumes, genetic factors, and respiratory infections such as pneumonia and bronchitis is also driving the market. The utilization of medications like bronchodilators, corticosteroids, and phosphodiesterase-4 inhibitors that enhance lung functioning is propelling the market growth. The market is benefiting from the elevating application of lung volume reduction surgery (LVRS) for serious COPD patients with significant emphysema, as it improves lung elasticity and breathing efficiency. The rising use of non-invasive ventilation techniques that improve oxygenation and breathing in severe COPD cases without resorting to invasive procedures like intubation or mechanical ventilation is set to stimulate the chronic obstructive pulmonary disease market further.
Countries Covered:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the chronic obstructive pulmonary disease market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the chronic obstructive pulmonary disease market
- Reimbursement scenario in the market
- In-market and pipeline drugs
This report also provides a detailed analysis of the current chronic obstructive pulmonary disease market drugs and late-stage pipeline drugs.
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug overview
- Mechanism of action
- Regulatory status
- Clinical trial results
- Drug uptake and market performance
Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: www.imarcgroup.com/request?type=report&id=7288&flag=C
Competitive Landscape With Key Players:
The competitive landscape of the chronic obstructive pulmonary disease market has been studied in the report with the detailed profiles of the key players operating in the market.
Key Highlights of the Report:
- Market Performance (2017-2022)
- Market Outlook (2023-2033)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: [email protected]
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com/
